237 related articles for article (PubMed ID: 32991668)
1. Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma.
Lee-Chang C; Miska J; Hou D; Rashidi A; Zhang P; Burga RA; Jusué-Torres I; Xiao T; Arrieta VA; Zhang DY; Lopez-Rosas A; Han Y; Sonabend AM; Horbinski CM; Stupp R; Balyasnikova IV; Lesniak MS
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 32991668
[TBL] [Abstract][Full Text] [Related]
2. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
Powell KL; Stephens AS; Ralph SJ
Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
[TBL] [Abstract][Full Text] [Related]
3. Antigen-presenting B cells promote TCF-1
Hou D; Wan H; Katz JL; Wang S; Castro BA; Vazquez-Cervantes GI; Arrieta VA; Dhiantravan S; Najem H; Rashidi A; Chia TY; Arjmandi T; Collado J; Billingham L; Lopez-Rosas A; Han Y; Sonabend AM; Heimberger AB; Zhang P; Miska J; Lee-Chang C
Front Immunol; 2023; 14():1295218. PubMed ID: 38268923
[TBL] [Abstract][Full Text] [Related]
4. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
Madireddi S; Schabowsky RH; Srivastava AK; Sharma RK; Yolcu ES; Shirwan H
PLoS One; 2012; 7(8):e42459. PubMed ID: 22870329
[TBL] [Abstract][Full Text] [Related]
5. CD4 T-cells transduced with CD80 and 4-1BBL mRNA induce long-term CD8 T-cell responses resulting in potent antitumor effects.
Park HM; Sohn HJ; Kim YJ; Cho HI; Kim TG
Vaccine; 2014 Dec; 32(51):6919-6926. PubMed ID: 25444817
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
8. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
9. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
[TBL] [Abstract][Full Text] [Related]
10. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
[TBL] [Abstract][Full Text] [Related]
11. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
[TBL] [Abstract][Full Text] [Related]
12. Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination.
Fromm G; de Silva S; Giffin L; Xu X; Rose J; Schreiber TH
Cancer Immunol Res; 2016 Sep; 4(9):766-78. PubMed ID: 27364122
[TBL] [Abstract][Full Text] [Related]
13. Targeting interferon-alpha to dendritic cells enhances a CD8
Graham JP; Authie P; Karolina Palucka A; Zurawski G
Vaccine; 2017 Aug; 35(35 Pt B):4532-4539. PubMed ID: 28743486
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
15. Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma.
Lookian PP; Zhao D; Medina R; Wang H; Zenka J; Gilbert MR; Pacak K; Zhuang Z
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810617
[TBL] [Abstract][Full Text] [Related]
16. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Lu ZY; Condomines M; Tarte K; Nadal L; Delteil MC; Rossi JF; Ferrand C; Klein B
Exp Hematol; 2007 Mar; 35(3):443-53. PubMed ID: 17309825
[TBL] [Abstract][Full Text] [Related]
17. Contribution of 4-1BBL on radioresistant cells in providing survival signals through 4-1BB expressed on CD8⁺ memory T cells in the bone marrow.
Lin GH; Edele F; Mbanwi AN; Wortzman ME; Snell LM; Vidric M; Roth K; Hauser AE; Watts TH
Eur J Immunol; 2012 Nov; 42(11):2861-74. PubMed ID: 22886791
[TBL] [Abstract][Full Text] [Related]
18. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
19. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
Zhu H; You Y; Shen Z; Shi L
Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
[TBL] [Abstract][Full Text] [Related]
20. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.
Yan X; Johnson BD; Orentas RJ
J Immunol; 2008 Oct; 181(7):4621-31. PubMed ID: 18802064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]